Q2 2025 Kamada Ltd Earnings Call Transcript
Key Points
- Kamada Ltd (KMDA) reported strong financial results for the first half of 2025, with total revenues of $88.8 million, representing an 11% year-over-year increase.
- Adjusted EBITDA for the first half of 2025 was $22.5 million, up 35% year-over-year, indicating improved profitability.
- The company increased its adjusted EBITDA guidance for 2025 to between $40 million and $44 million, reflecting confidence in continued profitable growth.
- Kamada Ltd (KMDA) is advancing its PIVOTAL phase 3 inhaled clinical program, which could lead to significant future growth opportunities.
- The company successfully launched its first biosimilar product in Israel and plans to launch two additional biosimilars later this year, contributing to future revenue growth.
- Gross profit margins decreased in the second quarter of 2025 compared to the same period in 2024, due to changes in product and territory sales mix.
- Operating expenses, although managed well, still represent a significant portion of revenues, which could impact future profitability if not controlled.
- The company's net income, while improved, is still subject to fluctuations due to changes in financial and tax expenses.
- The competitive landscape for Kamada Ltd (KMDA)'s inhaled AAT program is evolving, with other companies developing alternative technologies that could impact market share.
- The company's cash position, although strong, has declined over the last couple of quarters, which may limit the scale of future business development and M&A activities.
Greetings and welcome to the Kamada Limited second quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Brian Ritchie, Managing Director of LifeSci Advisors.
Thank you. You may begin.
Thank you. This is Brian Ritchie with LifeSci Advisors. Thank you all for participating in today's call. Joining me from Kamada are Amir London, Chief Executive Officer, and Chaime Orlev, Chief Financial Officer. Earlier today, Kamada announced its financial results for the three months and month months ended June 30, 2025. If you have not received this news release, please go to the investors page of the company's website at www.kamada.com.
Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements that involve risks and uncertainties regarding the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
